Skip to main content

Table 1 Demographics, clinical features, and treatments for patients with Degos disease

From: Clinical and laboratory prognosticators of atrophic papulosis (Degos disease): a systematic review

 

All Patients

MAP

BAP

Number of patients

105

67

38

Male/female (ratio)

47/58 (1:1.2)

35/32 (1.1:1)

12/26 (1:2.2)

Mean age of cutaneous onset (stdev)

35 (0–75)

35 (0–75)

35 (0.2–63)

Familial occurrence, n (%)

5/22 (22.7)

2/14 (14.3)

3/8 (37.5)

Mortality, n (%)

N/A

48/67 (71.6%)

N/A

Mean follow up time of study

2.55 (3.01)

2.20 (2.69)

3.36 (3.53)

Distribution of lesions, n (%)

   

 Generalized

95/104 (91.3)

61/66 (92.4)

34/38 (89.5)

 Localized

9/104 (8.7)

5/66 (7.6)

4/38 (10.5)

Primary or secondary Degos, n (%)

 Primary

94/105 (89.5)

63/67 (94)

31/38 (81.6)

 Secondary

11/105 (10.5)

4/67 (6.0)

7/38 (18.4)

 Dermatomyositis

2/105 (1.9)

0/67 (0)

2/38 (5.3)

 Relapsing polychondritis

1/105 (1)

0/67 (0)

1/38 (2.6)

 Rheumatoid arthritis

1/105 (1)

1/67 (1.5)

0/38 (0)

 Systemic lupus erythematosus

8/105 (7.6)

2/67 (3)

6/38 (15.8)

Treatments, n (%)

 Anticoagulant

20/93 (21.5)

19/63 (30.2)

1/30 (3.3)

 Antiplatelet (Single)

29/93 (31.2)

21/63 (33.3)

8/30 (26.7)

 Antiplatelet (Dual)

19/93 (20.4)

14/63 (22.2)

5/30 (16.7)

Biologics

 Eculizumab

8/93 (8.6)

8/63 (12.7)

0/30 (0)

 Infliximab

3/93 (3.2)

3/63 (4.8)

0/30 (0)

 Natalizumab

1/93 (1.1)

1/63 (1.6)

0/30 (0)

 Rituximab

2/93 (2.2)

2/63 (3.17)

0/30 (0)

 Corticosteroids (topical and oral)

39/93 (41.2)

31/63 (49.2)

8/30 (26.7)

Immunomodulators

 Aminosalicylates

1/93 (1.1)

1/63 (1.6)

0/30 (0)

 Azathioprine

2/93 (2.2)

1/63 (1.6)

1/30 (3.3)

 Cyclosporin A

3/93 (3.2)

2/63 (3.2)

1/30 (3.3)

 IVIg

13/93 (14)

11/63 (17.5)

2/30 (6.6)

 Methotrexate

4/93 (4.3)

2/63 (3.2)

2/30 (6.6)

 Tacrolimus

2/93 (2.2)

1/63 (1.6)

1/30 (3.3)

 Thalidomide

1/93 (1.1)

1/63 (1.6)

0/30 (0)

 Prostaglandin

2/93 (2.2)

1/63 (1.6)

1/30 (3.3)

Steroid sparing agents

 Cyclosporine

2/93 (2.2)

2/63 (3.2)

0/30 (0)

 Dapsone

2/93 (2.2)

1/63 (1.6)

1/30 (3.3)

Others

 Cyclophosphamide

7/93 (7.5)

7/63 (11.1)

0/30 (0)

 Pentoxifylline

9/93 (9.7)

6/63 (9.52)

3/30 (10)

 No Treatment

7/93 (7.5)

1/63 (1.6)

6/30 (20)

 Not Reported

12/93 (12.9)

4/63 (6.4)

8/30 (26.7)

Abnormal labs, n (%)

 ESR/CRP

14/76 (18.4)

13/48 (27.1)

1/28 (3.6)

 ANA

10/75 (13.3)

4/46 (8.7)

6/29 (20.1)

Patient geographic distribution, n (%)

 Asia

33/105 (31.4)

23/67 (34.3)

10/38 (26.3)

 North America

28/105 (26.7)

17/67 (25.4)

11/38 (28.9)

 South America

2/105 (1.9)

2/67 (3)

0/38 (0)

 Europe

38/105 (36.2)

22/67 (32.8)

16/38 (42.1)

 Africa

0/105 (0)

0/67 (0)

0/38 (0)

 Australia

4/105 (3.8)

3/67 (4.5)

1/38 (2.6)

  1. MAP, malignant atrophic papulosis; BAP, benign atrophic papulosis; N/A, not applicable